3rd Epigenetics in Drug Discovery conference

GTC’s 3rd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel epigenetic mechanisms, therapeutics, developments, biomarkers and diagnostics. Venture Capitalists will also join the conference to discuss investment opportunities and what they look for in the epigenetics space.

Some key discussions around epigenetics drug discovery at the conference include: 1) The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc. 2) Novel mechanisms, biomarkers, technologies and diagnostics for epigenetics drug discovery 3) Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Astex, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc.

Conference sessions are:
Epigenetic Mechanisms
Role of Epigenetics in Human Diseases
Drug Discovery in Epigenetics
Preclinical and Clinical Development
Epigenetic Biomarkers and Diagnostics
Panel Discussion: Investment Opportunities in the Epigenetic Space
+ show speakers and program
KEYNOTE SPEAKERS

Yi Zhang
Investigator, HHMI
Senior Investigator, PCMM
Boston Children's Hospital
Professor, Dept. Genetics & Dept. of Pediatrics
Harvard Medical School

Steve Baylin
Professor of Oncology, Deputy Director of the Cancer Center
Johns Hopkins University

FEATURED SPEAKER

Gary S. Stein
Chair of the Department of Biochemistry;
Co-director, Vermont Cancer Center for Basic and Translational Research
Harvard Medical School and Massachusetts General Hospital Cancer Center

DISTINGUISHED SPEAKERS AND PANELISTS
Olena Barbash
Principal Investigator, Cancer Epigenetics
GlaxoSmithKline

Ho Man Chan
Research Investigator, Oncology
Novartis

Timothy Chan
Physician, scientist, Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center

Gavin Choy
Vice President, Clinical Sciences and Operations
Astex Pharmaceuticals

Michael Cosgrove
Associate Professor, Biochemistry and Molecular Biology
SUNY Upstate Medical University

Antje Dittmann
Cellzome GmbH – a GSK company

Brian M. Gallagher
Partner
SR One

Roland Baumgartner
Director Translational Pharmacology
4SC AG

Ram Madabhushi
Post Doc, Johannes Graeff's Lab
MIT

Tamara Maes
CSO
Oryzon

Sriharsa Pradhan
Division Head, RNA Biology and Epigenetics
New England Biolabs

Kiran Reddy
Principal
Third Rock Ventures

David Shechter
Assistant Professor, Department of Biochemistry
Albert Einstein College of Medicine of Yeshiva University

Romesh R. Subramanian
Director, Biology
RaNA Therapeutics

John Trzupek
Principal Scientist, BioTherapeutics External Chemistry Innovation
Pfizer

Johnathan R. Whetstine
Assistant Professor of Medicine
Harvard Medical School and Massachusetts General Hospital Cancer Center

Peter R. Young
Senior Vice President, Discovery Research
Resverlogix

Keji Zhao
Senior Investigator and Director, Systems Biology Center
National Heart, Lung and Blood Institute

Sunny Zhou
Department of Chemistry and Chemical Biology
Northeastern University

Yujun George Zheng
Associate Professor, Chemistry, Georgia Cancer Coalition Distinguished Scholar
Johns Hopkins University


8 May - 10 May 2013
Boston
United States of America
meeting website